Drug Used to Reduce Preterm Birth Risk Should be Taken off Market: FDA Committee - Health, Medical and Fitness News Blog

Home Top Ad

Post Top Ad

Tuesday, November 05, 2019

Drug Used to Reduce Preterm Birth Risk Should be Taken off Market: FDA Committee

Drug Used to Reduce Preterm Birth Risk Should be Taken off Market: FDA Committee

Makena, a drug used to reduce the risk of preterm births, should be taken off the U.S. market, a Food and Drug Administration advisory committee recommends.

The 9-7 vote in favor of withdrawing approval of the drug came in response to evidence suggesting it's not effective, CNN reported.

While not required to, the FDA often follows the advice of its advisory committees.

Makena - a progestin hormone administered as an injection - was approved by the FDA in 2011 to reduce the risk of preterm birth in women who have a history of spontaneous preterm birth, CNN reported.

The recommendation by the Bone, Reproductive and Urologic Drugs Advisory Committee to halt sales of the drug came in the wake of findings from a study published last week in the American Journal of Perinatology.

After the study was published, the Society for Maternal-Fetal Medicine issued updated clinical guidance telling health care providers to inform patients about "uncertainty regarding the benefit" of the drug, CNN reported.

The American College of Obstetricians and Gynecologists said its clinical guidance on Makena will remain in effect.

"ACOG's guidance is based on a review of the best available literature. As such, we will continue to monitor this topic, evaluate additional literature and any further analyses as published, and address findings as needed in relevant clinical guidance," Dr. Christopher Zahn, vice president for practice activities, said in the statement.

Makena is made by AMAG Pharmaceuticals, which was disappointed by the FDA committee's vote, the company's chief medical officer said in a statement, CNN reported.

"We are committed to working with the FDA to identify feasible ways to generate additional efficacy data on Makena while retaining current access to the therapy for at-risk pregnant women," Dr. Julie Krop said.



Subscribe to Our Posts via Email


Share This

No comments:

Post Bottom Ad



NAVIGATION